C-kit ligand (SCF) in human multiple myeloma cells
- 1 January 1996
- journal article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 20 (5-6) , 457-464
- https://doi.org/10.3109/10428199609052429
Abstract
Here we review our recent experience addressing the role of SCF in multiple myeloma (MM). We first investigated the proliferation of MM cell lines and bone marrow samples from myeloma patients in response to rh-SCF alone and combined with Interleukin-6 (IL-6). IL-3. and IL-3/GM-CSF fusion protein PIXY 321. Neoplastic plasma cells were highly purified (>90%) by immunomagnetic depletion of T, myeloid, monocytoid and NK cells. The number of S-phase cells was evaluated after 3 days of liquid culture by the bromodeoxyuridine (BRDU) incorporation assay. The proliferation of RPMI 8226 and U266 cell lines was also assessed by a clonogenic assay. All the experiments were performed in serum-free conditions. RPMI 8226 cell line was not stimulated by SCF which also did not augment the proliferative activity of IL-6, IL-3 and PIXY-32I. Conversely, SCF addition resulted in 2.4-fold increase of the number of U266 colonies and in a higher number of U266 and MT3 cells in S-phase. The c-kit ligand also enhanced the proliferation of MT3 and U266 cells mediated by the other cytokines. Anti-SCF polyclonal antibodies completely abrogated the proliferative response of MT3 cells to exogenous SCF and markedly reduced the spontaneous growth of the same cell line. Reverse transcriptase-polymerase chain reaction amplification (RT-PCR) did detect SCF mRNA in MT3 and RPMI 8226 cells. Moreover, secreted SCF was found, in a biologically active form, in the supernatant of the two cell lines by the M07e proliferation assay. These results suggest that an au-tocrine proliferative loop may be operative in MT3 cell line. When tested on fresh myeloma samples, SCF increased the number of S-phase plasma cells (4.7 ± 1.6% vs 3.4 ± 1.3% in control cultures; p = 0.02). Significant proliferation was also induced by IL-6, IL-3 and PIXY-321. The addition of SCF significantly enhanced the proliferation of myeloma cells responsive to IL-6. Preliminary experiments performed on circulating plasma cells and myeloma precursors further supported the role of SCF on the proliferation of the neoplastic clone in MM.Keywords
This publication has 34 references indexed in Scilit:
- Long-term generation of colony-forming cells in liquid culture of CD34+ cord blood cells in the presence of recombinant human stem cell factorBlood, 1992
- Lack of a role of interleukin 11 in the growth of multiple myelomaLeukemia Research, 1992
- 'Role of bone marrow stromal cells in the growth of human multiple myelomaBlood, 1991
- Effect of murine mast cell growth factor (c-kit proto-oncogene ligand) on colony formation by human marrow hematopoietic progenitor cellsBlood, 1991
- Granulocyte-macrophage colony-stimulating factor synergizes with interleukin-6 in supporting the proliferation of human myeloma cells [see comments]Blood, 1990
- Molecular cloning of a cDNA encoding interleukin 11, a stromal cell-derived lymphopoietic and hematopoietic cytokine.Proceedings of the National Academy of Sciences, 1990
- The hematopoietic growth factor KL is encoded by the SI locus and is the ligand of the c-kit receptor, the gene product of the W locusCell, 1990
- Stem cell factor is encoded at the SI locus of the mouse and is the ligand for the c-kit tyrosine kinase receptorCell, 1990
- Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6Blood, 1989
- The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locusNature, 1988